Brief: Pasithea Therapeutics Announces FDA Acceptance Of IND Application To Evaluate Pas-004 In Advanced Cancer Patients
02/01/2024 13:37
Jan 2 (Reuters) - Pasithea Therapeutics Corp KTTA.O :
* PASITHEA THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF IND
APPLICATION TO EVALUATE PAS-004 IN ADVANCED CANCER PATIENTS
* INITIAL READOUT EXPECTED AS EARLY AS Q3 2024
* PHASE 1 DOSE ESCALATION STUDY IN PATIENTS WITH MAPK
PATHWAY
DRIVEN ADVANCED SOLID TUMORS TO BEGIN IN Q1 2024
* PAS-004 IS EXPECTED TO BE ONCE DAY OR LESS FREQUENT DOSE
WHICH
MAY PROVIDE BETTER COMPLIANCE RATES AS WELL AS SUPERIOR EFFICACY
Source text for Eikon: ID:nGNX2blt0K
Further company coverage: KTTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement